NCT04954014 (BEVACOR) is a Phase 2 clinical trial of Bevacizumab in ARDS, Human, sponsored by Maimónides Biomedical Research Institute of Córdoba.

Who is sponsoring NCT04954014?

NCT04954014 is sponsored by Maimónides Biomedical Research Institute of Córdoba.

What drugs are being tested in NCT04954014?

Interventions in NCT04954014: Bevacizumab, BAT.

What condition does NCT04954014 study?

NCT04954014 studies ARDS, Human, Coronavirus Infection.

Is NCT04954014 still recruiting?

NCT04954014 is currently terminated. Last updated 5 September 2021.

Last reviewed 2021-09-05 · How we verify

NCT04954014: BEVACOR

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pilot Study of Single Dose Bevacizumab as Treatment for Acute Respiratory Distress Syndrome (ARDS) in COVID-19 Patients

Terminated Phase 2 Last updated 5 September 2021

What this trial tests

Phase 2 trial testing Bevacizumab in ARDS, Human in 21 participants. Terminated before completion.

Timeline

1 September 2020

Primary endpoint
31 August 2021

31 August 2021

Quick facts

Lead sponsor	Maimónides Biomedical Research Institute of Córdoba
Phase	Phase 2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	21
Start date	1 September 2020
Primary completion	31 August 2021
Estimated completion	31 August 2021
Sites	1 location across Spain

Drugs / interventions tested

Bevacizumab (Bevacizumab-Bvzr) — full drug profile →
BAT (bat) — full drug profile →

Conditions studied

ARDS, Human — all drugs for ARDS, Human →
Coronavirus Infection — all drugs for Coronavirus Infection →

Sponsor

Maimónides Biomedical Research Institute of Córdoba

Who can join

Adults 18 to 90, any sex, with ARDS, Human or Coronavirus Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Our hypothesis is that treating ARDS caused by COVID-19 with bevacizumab improves mortality. This is a phase II, multi-centered, randomized, open label, two-armed clinical trial to study the safety and efficacy of bevacizumab in COVID-19 positive patients who consequently developed ARDS (acute respiratory distress syndrome) and who have previously received anti-viral and anti-inflammatory treatment.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Inflammatory pathways in COVID-19: Mechanism and therapeutic interventions.
Jiang Y, Zhao T, Zhou X, Xiang Y, et al · · 2022 · cited 44× · PMID 35923762 · DOI 10.1002/mco2.154
COVID-19-Associated acute respiratory distress syndrome (CARDS): Mechanistic insights on therapeutic intervention and emerging trends.
Thapa K, Verma N, Singh TG, Kaur Grewal A, et al · · 2021 · cited 7× · PMID 34768236 · DOI 10.1016/j.intimp.2021.108328

Verify or expand the search:

Other trials of Bevacizumab

Trials testing the same drug.

NCT07504588 — Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and · Phase 2 · not yet recruiting
NCT07500298 — Phase 1 Study Of SAR445877 In Combination With FOLFOX6 And Bevacizumab As First-Line Treatment For Microsatellite Stable · Phase 1 · not yet recruiting
NCT07271355 — Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colore · Phase 3 · not yet recruiting
NCT07318389 — ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer · EARLY_PHASE1 · not yet recruiting
NCT07535632 — SBRT Followed by PD-1 Inhibitor, Bevacizumab and TAS-102 as Third-Line Therapy for Recurrent/Metastatic Colorectal Cance · Phase 2 · not yet recruiting

Other recruiting trials for ARDS, Human

Currently open trials in the same condition.

NCT07070362 — Digital Early Warning System for Acute Lung Injury in Liver Surgery · recruiting
NCT06572280 — Non-invasive Phrenic Nerve Stimulation in ARDS Patient · NA · recruiting
NCT06119516 — Transpulmonary Pressure - Guided Mechanical Ventilation in Morbidly Obese ARDS Patients: a Feasibility Study. · NA · recruiting
NCT06321497 — Extracorporeal Carbon Dioxide Removal Using PrismaLung in Reducing Ventilator Induced Lung Injury · recruiting
NCT06486259 — Regional Assessment of the Risk of Lung Injury in Ventilated Patients · recruiting

Other Maimónides Biomedical Research Institute of Córdoba trials

Trials by the same sponsor.

NCT06783491 — Efficacy of the Use of Neoadjuvant With/Without Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Locally Ad · Phase 3 · not yet recruiting
NCT07479303 — Vitamin D Status in Young Medical Residents · completed
NCT07178379 — Hysteroscopy Anesthesia for Relief of Pain · NA · not yet recruiting
NCT06712485 — Biomarkers in EV Associated With Marrow Adiposity in Anorexia · not yet recruiting
NCT06579846 — 12-Month Efficacy of Exercise and Cytisinicline for Tobacco Abstinence · Phase 4 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04954014 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Maimónides Biomedical Research Institute of Córdoba
Last refreshed: 5 September 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04954014.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing